FTC (US Federal Trade Commission) plans to block Cytyc/Digene deal
This article was originally published in Clinica
Executive Summary
Shares in Cytyc and Digene plummeted after the US Federal Trade Commission (FTC) said it would block Cytyc's proposed acquisition of Digene because of anti-trust concerns, writes Imogen Daulby. The FTC later agreed not to begin its suit yet, provided Cytyc agreed to give the FTC 10 days' written notice of any action to complete the deal, at which point the FTC would be free to act.